UBS cuts Siegfried Holding to 'neutral' on modest growth prospects
BUZZ-UBS cuts Siegfried Holding to 'neutral' on modest growth prospects ** Swiss pharmaceutical company Siegfried Holding SFZN.S is down around 4% after UBS cut it to "neutral" from "buy"
** Growth in 2026 will likely be modest and weighted to H2, with uncertainty around demand from key customers and recent acquisitions contributing less in the near term, the broker says
** The broker estimates earnings per share to be around 7% lower in FY26-28 due to delays in new capacity coming online
** The stock looks reasonably priced, with both upside and downside risks balanced, so it's better to wait for clearer growth signals before investing, the broker says
** Shares are at their lowest level since November 2025
** Out of 12 brokerages covering the stock, 8 rate it "strong buy" or "buy" and 4 "hold" - LSEG data
(Reporting by Emanuele Berro)